EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Viral load suppression and HIV-1 drug resistance mutations in persons with HIV on TLD/TAFED in Zambia

Emmanuel L Luwaya iD, Lackson Mwape, Kaole Bwalya iD, Chileleko Siakabanze, Benson M Hamooya, Sepiso K Masenga

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0308869 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Emmanuel L Luwaya und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine and Health Sciences, Mulungushi University, Livingstone, Zambia. Hauptthemen laut MEDLINE: HIV-1, HIV Infections, Drug Resistance, Viral, Viral Load. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: American Heart Association-American Stroke Association, FIC NIH HHS, Fogarty International Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

An increase in the prevalence of HIV drug resistance (HIVDR) has been reported in recent years, especially in persons on non-nucleoside reverse transcriptase inhibitors (NNRTIs) due to their low genetic barrier to mutations. However, there is a paucity of epidemiological data quantifying HIVDR in the era of new drugs like dolutegravir (DTG) in sub-Saharan Africa. We, therefore, sought to determine the prevalence and correlates of viral load (VL) suppression in adult people with HIV (PWH) on a fixed-dose combination of tenofovir disoproxil fumarate/lamivudine/dolutegravir (TLD) or tenofovir alafenamide/emtricitabine/dolutegravir (TAFED) and describe patterns of mutations in individuals failing treatment.

Methods

We conducted a cross-sectional study among 384 adults living with HIV aged ≥15 years between 5 th June 2023 and 10 th August 2023. Demographic, laboratory and clinical data were collected from electronic health records using a data collection form. Viral load suppression was defined as plasma HIV-1 RNA VL of

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1HIV InfectionsDrug Resistance, ViralViral LoadMutationTenofovirAnti-HIV AgentsPiperazinesLamivudinePyridonesHumansFemaleAdultMaleZambiaCross-Sectional StudiesOxazinesHeterocyclic Compounds, 3-RingEmtricitabineMiddle AgedYoung AdultAdolescentDrug CombinationsDolutegravir

Substanzen

TenofovirAnti-HIV AgentsPiperazinesLamivudinePyridonesOxazinesHeterocyclic Compounds, 3-RingEmtricitabineDrug CombinationsDolutegravir

Autor:innen und Institutionen

  • School of Medicine and Health Sciences, Mulungushi University, Livingstone, Zambia.
  • Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.

ORCID-Profile: Emmanuel L Luwaya, Kaole Bwalya

Förderung

  • American Heart Association-American Stroke Association
  • FIC NIH HHS
  • Fogarty International Center
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • American Heart Association

Zitieren

APA

Luwaya, E. L., Mwape, L., Bwalya, K., Siakabanze, C., Hamooya, B. M., & Masenga, S. K. (2024). Viral load suppression and HIV-1 drug resistance mutations in persons with HIV on TLD/TAFED in Zambia. PLOS ONE. https://doi.org/10.1371/journal.pone.0308869

Vancouver

Luwaya EL, Mwape L, Bwalya K, Siakabanze C, Hamooya BM, Masenga SK. Viral load suppression and HIV-1 drug resistance mutations in persons with HIV on TLD/TAFED in Zambia. PLOS ONE. 2024. doi:10.1371/journal.pone.0308869

BibTeX
@article{Luwaya2024,
  author = {Luwaya, Emmanuel L and Mwape, Lackson and Bwalya, Kaole and Siakabanze, Chileleko and Hamooya, Benson M and Masenga, Sepiso K},
  title = {Viral load suppression and HIV-1 drug resistance mutations in persons with HIV on TLD/TAFED in Zambia},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0308869}
}
Kostenlos starten →